UNSPSC 51422336: Dexamethasone dipropionate

This classification denotes a therapeutic glucocorticoid with the molecular formula C28H37FO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K3UKR54YXW, chemically known as 9-fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate but more generally known as dexamethasone dipropionate, which bears US NIH Compound Identifier 63049. European Medicines Agency schedules Dexamethasone dipropionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01609MIG.

UNSPSC 51422336 Dexamethasone dipropionate is a Commodity code that in recent state and local practice encompasses pharmaceutical procurement for community health and pharmacy benefit programs, though the code shows significant mismatch with actual solicitation scope. The recent opportunities tagged under this code involve procurement of naloxone and drug deactivation systems for emergency response and public health initiatives, as well as direct-to-manufacturer prescription program capabilities — neither of which aligns with the code's nominal specification of a single corticosteroid pharmaceutical. State and local issuing bodies soliciting under this code include county health departments and state health and human services agencies, though the small recent-opportunity sample suggests limited and fragmented activity in this narrow pharmaceutical category.

Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, for quarterly delivery to the Seminole County Community Health Building in Sanford, with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription programs for the state's pharmacy benefit initiative, posted in advance of a planned formal RFP. The geographic spread is limited to Florida and Texas in recent activity. The code shows sparse recent procurement volume overall, and the tagged opportunities center on naloxone and pharmacy program structure rather than corticosteroid supply, suggesting either persistent classification misalignment or narrowly episodic demand for the code's stated pharmaceutical.